Trial record 13 of 25 for:    Neuroleptic Malignant Syndrome

A Feasibility Study of the Impact on Blood Pressure Control of Supplementing Community Pharmacist Services With Structured Information on Blood Pressure and Its Treatment

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by University of Warwick
Sponsor:
Information provided by (Responsible Party):
Ejaz Cheema, University of Warwick
ClinicalTrials.gov Identifier:
NCT01939860
First received: September 3, 2013
Last updated: February 28, 2014
Last verified: February 2014
  Purpose

Hypertension is a major health problem, however its control is unsatisfactory. One of the reasons for such a high prevalence of this disease includes poor patient compliance to treatment. Approximately 30 % of newly diagnosed hypertensive patients stop taking their blood pressure medication by six months and 50% by 12 months.

The UK government is keen to encourage community pharmacists to play an active role in participation of services that can improve patient adherence to their medications. The New Medicines Service (NMS) and targeted Medicines Use Reviews (MUR) are established services which fund community pharmacists to review and explain medicine use to patients, with hypertension a common condition for which advice is given within these schemes. Within these schemes, advice is verbal and unstructured, with no specific written information provided on drugs or the disease being treated.

This study aims to determine whether structured information provided to participants verbally and in writing by community pharmacists about blood pressure and current medicine(s) within NMS and targeted MURs will be retained and will be associated with improved hypertension control. Participants will be recruited from people eligible for NMS and MURs and attending community pharmacies.


Condition Intervention
Hypertension
Other: Written and verbal patient education on hypertension and its treatment

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by University of Warwick:

Primary Outcome Measures:
  • Changes in systolic or diastolic blood pressure [ Time Frame: one year ] [ Designated as safety issue: No ]
    Systolic and diastolic blood pressure will be measured and recorded in mm Hg using OMRON blood pressure monitors


Secondary Outcome Measures:
  • Changes in the number of New medicine services interventions completed by the pharmacists [ Time Frame: one year ] [ Designated as safety issue: No ]

Estimated Enrollment: 132
Study Start Date: December 2013
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Usual pharmacy care
Participants will not receive any structured written education on hypertension and its treatment
Experimental: usual pharmacy care plus structured information
Participants will be provided with validated verbal and written information on hypertension and its treatment, including information about class (es) of anti-hypertensive medication(s) used by each patient, and their common side-effects. The written material will be based on validated patient information leaflets from the British Heart Foundation and the Blood Pressure Association.
Other: Written and verbal patient education on hypertension and its treatment

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1)18 or over 2) male or female 3) Have been started on any blood pressure medication

Exclusion Criteria:

1)Patients with English language problems

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01939860

Locations
United Kingdom
J P Goes chemist Recruiting
Coventry, United Kingdom
Contact: John Goes       johngoes1@gmail.com   
Sponsors and Collaborators
University of Warwick
  More Information

No publications provided

Responsible Party: Ejaz Cheema, PhD student, University of Warwick
ClinicalTrials.gov Identifier: NCT01939860     History of Changes
Other Study ID Numbers: Warwick.123
Study First Received: September 3, 2013
Last Updated: February 28, 2014
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 19, 2014